🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Achieve Life Sciences, Inc. ACHV R3KPHARMA

Healthcare · Biotechnology · United States
https://www.achievelifesciences.com
Company Profile ↓
$7.84
+208.66% 1Y
Mkt Cap$806.76M
P/E-4.72
P/B-52.73
52W High$8.53
52W Low$2.54
Book Value$-0.14
EPS (TTM)$-1.66

Company Overview

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Growth & Price Performance

Stock Price Performance

1 Year:+208.66%
6 Months:+85.78%
3 Months:+43.07%
1 Month:+17.89%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 88% of range
$2.54 $8.53
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)53.56 · Neutral
Price Performance
1M+17.89%
3M+43.07%
6M+85.78%
1Y+208.66%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.72
Industry PE
24.83
Forward P/E
-12.32
PEG Ratio
17.68
Book Value
$-0.14
Price to Book
-52.73
P/S
-
EV/EBITDA
-10.93
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-29.21%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.19
EPS (TTM)
$-1.66

Balance Sheet & Liquidity

Debt/Equity
1.40
Quick Ratio
0.95
Current Ratio
0.95
Debt
$14.95M
Total Assets
$33.10M
Current Assets
$31.06M
Working Capital
$30.81M

Ownership

Promoter Holding
0.91%
Chg in Prom Hold
-0.02%
FII / Inst Holding
81.97%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$806.76M
Total Revenue (TTM)
$0
EBITDA
$-58.05M
Free Cash Flow
$156.32M
Operating Cash Flow
$-47.02M
Shares Outstanding
102.90M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ACHV Achieve Life Sciences, Inc. R3KPHARMA 7.84 -4.72 $806.76M 0.00% - - - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------------------------------00000
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------12.89M12.56M14.69M14.73M10.46M
Operating Income ------------------------------------12.89M-12.56M-14.69M-14.73M-10.46M
EBITDA ------------------------------------12.58M-12.47M-14.20M-14.35M-9.84M
Interest Expense -----------------------------------185.00K191.00K192.00K251.00K274.00K
Pretax Income ------------------------------------12.83M-12.72M-14.44M-14.66M-10.17M
Tax Provision ----------------------------------------
Net Income -1.72M-242.00K-238.00K-268.00K-486.00K-205.00K-169.00K-6.47M-3.74M-3.02M-2.79M-3.24M-3.64M-5.90M-3.62M-3.67M-3.19M-3.32M-2.92M-3.76M-4.72M-8.00M-11.31M-6.69M-7.15M-7.57M-10.47M-13.08M-8.99M-8.24M-7.11M-6.49M-8.46M-12.51M--12.83M-12.72M-14.44M-14.66M-10.17M
Diluted EPS -----------------------1.53-0.71--0.80-1.08-1.35-0.50-0.43-0.34-0.26-0.25-0.36--0.37-0.37-0.28-0.28-0.19
R&D Expense 6.59M65.00K72.00K69.00K80.00K61.00K62.00K825.00K2.15M1.20M1.04M1.54M2.08M4.05M2.03M1.82M1.76M1.54M1.10M1.89M2.35M5.64M9.23M4.59M4.51M4.39M7.21M9.87M5.53M4.58M3.58M2.80M5.11M7.61M-7.10M6.71M5.32M--

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------00--0000
Cost of Revenue -----------------
Gross Profit -----------------
Operating Expenses -------------40.80M27.25M39.07M54.88M
Operating Income --------------40.80M-27.25M-39.07M-54.88M
EBITDA --------------40.33M-26.73M-37.42M-53.60M
Interest Expense -------------1.79M2.85M2.18M819.00K
Pretax Income --------------42.35M-29.82M-39.83M-54.65M
Tax Provision -----------------
Net Income -5.48M-12.58M-14.67M-21.10M-31.85M-26.24M-828.00K-1.23M-10.58M-12.69M-16.39M-14.73M-33.15M-42.35M-29.82M-39.83M-54.65M
Diluted EPS ------------5.42-4.08-4.00-1.50-1.24-1.25
R&D Expense 20.21M18.48M21.55M39.95M55.32M46.22M25.11M286.00K3.10M5.87M9.67M6.88M23.97M30.08M15.81M22.82M-

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014May 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --89.92M68.02M82.02M55.69M56.29M-58.21M3.81M9.89M19.08M21.08M40.30M-29.97M19.37M38.63M41.79M
Current Assets ---------------27.33M16.98M36.47M39.89M
Cash & Equivalents 7.62M62.05M23.53M28.52M18.07M14.59M27.90M-34.31M15.00K5.28M9.52M16.66M35.85M-24.72M15.50M12.73M20.91M
Inventory -------------------
Receivables --------------153.00K105.00K111.00K0-
Total Liabilities --45.79M37.12M15.81M18.48M22.23M-20.77M3.20M2.01M3.28M3.03M3.01M-21.67M20.82M17.73M20.27M
Current Liabilities --27.48M30.79M11.56M14.93M22.22M-20.66M3.07M2.01M3.27M2.87M2.94M-21.60M20.81M6.68M9.08M
Long Term Debt --------------14.92M--9.84M11.19M
Total Debt ---------------16.20M16.73M9.96M14.96M
Total Equity 10.71M22.96M44.12M30.89M66.21M37.21M34.06M01.84M610.00K15.80M15.80M18.05M37.29M-8.30M-1.45M20.90M21.52M
Shares Outstanding ---------------17.90M21.17M34.69M53.23M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 34.88M-26.84M-20.26M-43.49M-35.93M---202.00K-9.11M-10.62M-15.22M-13.47M--37.57M-24.48M-29.77M-49.47M
Investing Cash Flow 2.23M-59.13M25.07M-21.19M32.43M---12.65M-5.12M5.04M-17.00K-0-21.00K-21.58M6.11M
Financing Cash Flow 17.35M47.48M219.00K54.24M10.00K--150.00K2.00M19.76M17.32M32.68M-19.32M15.28M48.53M51.53M
Capital Expenditure -15.00K-68.00K-79.00K-291.00K-253.00K-82.00K-371.00K-46.00K--46.00K-53.00K-17.00K---21.00K--4.00K
Free Cash Flow 34.86M-26.91M-20.34M-43.78M-36.18M---248.00K--10.67M-15.27M-13.49M--37.57M-24.50M-29.77M-49.47M
Net Change in Cash --------------18.25M-9.22M-2.82M8.17M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % -----------------
Net Margin % -----------------
ROE % -23.9%-28.5%-47.5%-31.9%-85.6%-77.0%-45.0%-202.3%-67.0%-80.3%-90.8%-39.5%--510.1%2,059.0%-190.6%-254.0%
ROCE % --------------487.3%1,889.7%-122.3%-167.8%

Shareholding Pattern

Insiders
0.91%
Institutions
81.97%
Public Float
82.72%

Top Institutional Holders

#Holder% HeldSharesValue
1 Frazier Life Sciences Management, L.P. 7.40% 7.61M $60.77M
2 TPG GP A, LLC 6.68% 6.88M $54.88M
3 venBio Partners LLC 5.75% 5.91M $47.20M
4 Logos Global Management LP 5.27% 5.42M $43.29M
5 Blackrock Inc. 5.12% 5.27M $42.07M
6 Franklin Resources, Inc. 4.81% 4.95M $39.53M
7 Paradigm Biocapital Advisors LP 4.81% 4.95M $39.52M
8 Vanguard Capital Management LLC 4.02% 4.14M $33.04M
9 Propel Bio Management, LLC 3.92% 4.03M $32.19M
10 Marshall Wace LLP 3.66% 3.77M $30.09M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ACHV

Yahoo Finance ue, 18 Aug 2026

ACHV: Looking Ahead to Resubmission

By John Vandermosten, CFA NASDAQ: ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ: ACHV) reported second quarter results, introducing a number of new faces and regulatory updates since the previous financial upda…

Yahoo Finance Wed, 12 Aug 2026

Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.

Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum. ACHV has surged 173% over 52 weeks. Shares recently hit a 3-year high earlier in …

Yahoo Finance ue, 11 Aug 2026

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Office…

Yahoo Finance Fri, 31 Jul 2026

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as…

Yahoo Finance Fri, 10 Jul 2026

Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting

Achieve Life Sciences (NASDAQ:ACHV) held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the…

Yahoo Finance Mon, 29 Jun 2026

Achieve Life Sciences Joins Russell 2000® Index

SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercializ…

ACHV — Frequently Asked Questions

What is the current share price of Achieve Life Sciences, Inc. (ACHV)?

As of 2026-09-19 21:16 PDT, Achieve Life Sciences, Inc. (ACHV) trades at $7.84 on NasdaqCM. Its 52-week range is $2.54 to $8.53.

What is the market capitalisation of ACHV?

Achieve Life Sciences, Inc. (ACHV) has a market capitalisation of $806.76M on NasdaqCM.

What is the P/E ratio of ACHV?

ACHV trades at a trailing price-to-earnings (P/E) ratio of -4.72. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -52.73.

Is ACHV a good stock to buy?

This page provides a data-driven analysis of Achieve Life Sciences, Inc. (ACHV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space